Protection of erythrocytes against hemolytic agents by cyclodextrin polysulfate.
Cyclodextrins generally exhibit hemolytic activity, some at concentrations as low as 1-10 mg/mL or lower. However, we found previously that a highly polysulfated cyclodextrin has no demonstrable hemolytic activity (Macarak et al., Biochem Pharmacol 42: 1502-1503, 1991). In the present study, we determined that, in fact, cyclodextrin polysulfate (CDS) actively protected erythrocytes against hemolysis induced by a wide spectrum of hemolytically active substances, ranging from pharmaceuticals, such as chlorpromazine, to solid suspensions of siliceous particles. The protective action was also effective against the hemolytic action of non-sulfated cyclodextrins. The similar kinetic responses of the erythrocytes to CDS protection against such chemically and structurally diverse hemolytic agents suggest a common mechanism involving the cell. Addition of the sulfated cyclodextrins to other cyclodextrin compounds used to solubilize poorly soluble pharmaceutical agents can extend the allowable maximum dosage without deleterious hemolytic action.
Weisz
P B
PB
Department of Chemical Engineering, University of Pennsylvania, Philadelphia 19104.
Kumor
K
K
Macarak
E J
EJ
D002478:Cells, Cultured; D002746:Chlorpromazine / Q000494:pharmacology; D003505:Cyclodextrins / Q000494:pharmacology*; D004336:Drug Antagonism; D004912:Erythrocytes / Q000187:drug effects*; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D013431:Sulfates / Q000494:pharmacology
D003505:Cyclodextrins; D013431:Sulfates; D002746:Chlorpromazine